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Abstract
Background: New erythrocyte parameters are report-
ed by the Sysmex XE 5000 analyzer. This instrument
measures the hemoglobin (Hb) content of individual
red cells, calculates the percentage of hypochromic
red cells (%Hypo He) and the percentage of hyper-
chromic red cells (%Hyper He) and quantifies the pro-
portion of marginally sized erythrocytes (%Micro R
and %Macro R). The goals of the study were to estab-
lish the reference range for erythrocyte extended
parameters, their value in different types of anemia
and to investigate their reliability in the study of dis-
orders of iron metabolism.
Materials: Three hundred and ninety samples were
analyzed. The Kolmogorov-Smirnoff test, independ-
ent samples t-test and Pearson correlation were
calculated; receiver operating characteristic (ROC)
curve analysis was used to determine their diagnostic
performance.
Results: The values of the four parameters studied
were normally distributed and statistically different
(p-0.0001) in the different groups of patients; the
only exception was %Hypo He in cases of iron defi-
ciency and thalassemia (ps0.3758). Results of ROC
curve analysis for %Hypo He in the diagnosis of
restricted erythropoiesis reticulocyte Hb content
(reticulocyte hemoglobin content, Ret He -29 pg)
were: area under the curve 0.963; cut-off 1.8%; sen-
sitivity 98.3%; specificity 91.1%.
Conclusions: The new parameters appear to be sen-
sitive for detecting small changes in the number of
red cells with inadequate hemoglobinization and
volume.
Clin Chem Lab Med 2009;47:1411–6.
Keywords: hypochromia; mature erythrocyte; micro-
cytosis; restricted erythropoiesis.
*Corresponding author: Dr. Eloı́sa Urrechaga, Hematology
Laboratory, Hospital Galdakao, Usansolo, 48960 Galdakao,
Vizcaya, Spain
Phone: q34 94 400 7102, Fax: q34 94 400 7128,
E-mail: eloisa.urrechagaigartua@osakidetza.net
Received April 20, 2009; accepted July 13, 2009;
previously published online October 12, 2009
Introduction
Iron metabolism is a dynamic process, which can-
not be defined by one biochemical or hematological
parameter only. Iron status is the result of the balance
between the rate of erythropoiesis and the size of iron
stores. Diagnostic tests for the evaluation of iron
metabolism status include indicators of disrupted
hemoglobin (Hb) synthesis, mature erythrocyte indi-
ces and biochemical markers of iron uptake, avail-
ability and stores (1).
Red blood cells are continuously produced in the
bone marrow. When iron deficiency manifests and
iron stores decrease, mean cell volume (MCV), mean
cell hemoglobin (MCH) and red blood cell count (RBC)
tend to decline.
The indices, MCV, MCH and mean cell hemoglobin
concentration (MCHC) represent the mean values
obtained for the total red cell population (2).
In contrast, modern hematology analyzers that
utilize flow cytometric analysis provide information
about individual cell characteristics, identifying small
subpopulations of erythrocytes within the total red
cell population.
To date, these measurements have been restricted
to analyzers from a single manufacturer, ADVIA series
(Siemens Medical Solutions Diagnostics, Tarrytown,
NY, USA). From simultaneous analysis of volume and
Hb concentration, this system provides quantitative
analysis of the RBC subpopulations and calculates
percentages for micro-, normo-, macrocytic cells, and
for the hypo-, normo- and hyperchromic RBCs (3).
Measurement of the proportion of hypochromic
and microcytic red cells is a useful way for detecting
small changes in the number of red cells with inade-
quate hemoglobinization (4–8). However, because of
the long circulating life span of mature erythrocytes,
the percentage of hypochromic cells is related to iron
status over the previous 2–3 months, and this para-
meter has been recognized as a reliable indicator of
functional iron deficiency.
Automated measurement of RBC microcytosis and
hypochromia have also proven their clinical useful-
ness in the differential diagnosis of iron deficiency
and b thalassemia trait (9–12).
The Sysmex XE 5000 instrument (Sysmex Corpor-
ation, Kobe, Japan) is a fully automated hematology
analyzer that provides complete blood cell and
leukocyte differential counts (13). Derived from flow
fluorescence cytometry technology, the analyzer
incorporates four new RBC parameters including:
• %Hypo He which indicates the percentage of hypo-
chromic red cells with an Hb content -17 pg.
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Table 1 Hematological and biochemical data for our study patients comprised of 90 healthy individuals, 124 with iron defi-
ciency anemia (IDA), 98 b thalassemia carriers and 78 patients with chronic kidney disease (CKD).
RBC, Hb, MCV, MCH, MCHC, Ret He, Iron, Transf, Ferritin, Sat,
1012/L g/L fL pg g/L pg mmol/L g/L mg/L %
Healthy, mean 4.95 151 90.9 30.5 335 33.8 17.1 2.46 103 28
(SD) (0.37) (9) (2.9) (0.9) (9) (1.4) (2.3) (0.3) (54) (7.5)
IDA, mean 4.12 97 74.2 23.2 304 25.2 4.8 3.00 25 7
(SD) (0.74) (17) (7.6) (3.1) (15) (4.8) (2.8) (0.7) (34) (4.3)
b Thal, mean 6.2 117 65.1 20.9 321 22.6 16.5 2.36 109 27
(SD) (1.3) (11) (3.5) (1.2) (66) (1.9) (6.1) (0.4) (99) (12)
CKD, mean 3.65 108 91.8 29.8 322 32.4 10.7 1.92 286 24
(SD) (0.5) (8) (5.9) (2.3) (15) (3.6) (5.7) (0.47) (188) (15)
SD, standard deviation; RBC, red blood cells; Hb, hemoglobin; MCV, mean cell volume; MCH, mean cell hemoglobin; MCHC,
mean cell hemoglobin concentration; Ret He, reticulocyte hemoglobin content; Transf, transferrin; % Sat, % transferrin satu-
ration; b Thal, b thalassemia.
• %Hyper He which indicates the percentage of
hyperchromic red cells with an Hb content )49 pg.
• %Micro R indicates the percentage of microcytic
red cells with a volume -60 fL.
• %Macro R indicates the percentage of macrocytic
red cells with a volume )120 fL.
Using these new parameters allows hemoglobini-
zation of marginally sized RBC to be monitored, while
measurement of the proportion of the small and large
RBC (based on their marginal volumes) completes the
analysis of RBC morphological details.
The goals of this study were to establish the refer-
ence range for RBC extended parameters in a normal
population, to establish their mean values in different
types of anemia and to investigate their correlation
with the other erythrocyte indices and reticulocyte
hemoglobin content (Ret He).
Materials and methods
Analytical methods
The Sysmex XE 5000 is a fully automated blood cell counter
(13).
The flow fluorescence cytometry technology enables inde-
pendent measurements of the volume and Hb content of
individual red cells to be performed.
Measurement of RBCs and platelets employs a Sheath
Flow DC detection method. The sample flow is focused on
the center of the aperture. Changing the generated electrical
resistance into pulses allows precise size distributions of
RBCs and platelets to be obtained. The percentage of red
cells subpopulations can be calculated and the new para-
meters %Micro R and %Macro R determined.
In the reticulocyte channel, blood cells are stained by
a polymethine dye that is specific for RNA/DNA, and then
analyzed with flow cytometry using a semiconductor laser.
A bi-dimensional distribution of forward scattered light
and fluorescence is presented as a scattergram, indicating
mature red cells and reticulocytes. Forward scatter correlates
with erythrocyte Hb content and Ret He. The percentage of
red cells subpopulations can be calculated and the new para-
meters %Hypo He and %Hyper He can be determined.
Patients
During a 3-month period, samples from 90 healthy individ-
uals (reference group), 124 patients with iron deficiency ane-
mia (IDA), 78 with chronic kidney disease (CKD) and 98 b
thalassemia carriers were collected in EDTA anti-coagulant
tubes (Vacutainer Becton-Dickinson, Rutherford, NJ, USA).
Samples were obtained from the routine workload and
prospectively analyzed on the Sysmex XE 5000 (Sysmex
Corporation, Kobe, Japan) within 6 h of collection.
Reference ranges for the new RBC extended parameters,
%Hypo He, %Hyper He, %Micro R and %Macro R, were
obtained from 45 male and 45 female healthy adult subjects,
with no clinical symptoms of disease and with results of the
complete blood count and biochemical markers of iron
metabolism within the normal reference range. Reference
ranges were calculated as the 95 central percentiles of the
distribution.
IDA patients fulfilled traditional diagnostic criteria for IDA
with serum iron -7.5 mmol/L, transferrin saturation -20%,
ferritin -100 mg/L, and Hb -110 g/L prior to treatment with
iron (14, 15).
CKD patients were managed according to the recommen-
dations of the NKF-K/DOQI (National Kidney Foundation, Kid-
ney Disease Outcomes Quality Initiative) anemia guidelines
(16). All patients were treated with various doses of eryth-
ropoietin given three times a week at the time of hemodial-
ysis. In addition, the majority of patients were treated with
a maintenance dose of intravenous iron (100–200 mg of iron
gluconate) weekly or every other week in order to maintain
Hb at the recommended concentration of 110–120 g/L.
The thalassemia group included patients with a previous
diagnosis of the disease. b thalassemia screening is routine-
ly performed in our laboratory by analysis of RBC indices
and the concentration of HbA2. Molecular characterization of
mutations is performed with allele specific oligonucleotide-
polymerase chain reaction (ASO-PCR) techniques (17, 18).
Samples with erythrocytosis (RBC)5.5=1012/L) and
microcytosis (MCV-70 fL) were selected for HbA2 quantita-
tion (HPLC HA 8160, Menarini Diagnostics, Florence, Italy).
Increased HbA2 ()3.5%) is considered to be confirmatory for
b thalassemia trait. Molecular analysis is performed if genet-
ic counseling is required. b Thalassemia carriers with ferro-
kinetic parameters within reference range were included,
only. Biochemical and hematological data of the patients are
summarized on Table 1.
Statistical evaluation of analytical results
The statistical software package SPSS version 16.0 for Win-
dows (SPSS; Chicago, IL, USA) was used for analysis of
results. The Kolmogorov-Smirnoff test was used to verify a
Gaussian distribution of RBC extended parameters values in
our normal population. Correlation coefficients between
erythrocyte indices and new RBC extended parameters were
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Figure 1 Comparison of %Hypo He (percentage of hypochromic red cells) between the three groups of patients with anemia:
iron deficiency anemia (IDA), thalassemia carriers, chronic kidney disease (CKD) and the reference group.
The horizontal line in the center of the box shows the median value, the upper and lower limits of the box show the inter-
quartile range, and the whiskers show the minimum and maximum values for each group.
Table 2 RBC extended parameters values, mean (standard deviation, SD), from 90 healthy individuals, 124 patients with iron
deficiency anemia (IDA), 98 b thalassemia carriers and 78 patients with chronic kidney disease (CKD).
Healthy Thalassemia IDA CKD Reference range
%Hypo He 0.3 (0.16) 14.2 (9.4) 16.2 (15.8) 1.7 (1.8) 0.0–0.6
%Hyper He 0.8 (0.16) 0.08 (0.07) 0.24 (0.2) 0.6 (0.18) 0.5–1.1
%Micro R 1.1 (0.44) 37.6 (11.5) 16.5 (13.1) 2.5 (2.4) 0.2–1.9
%Macro R 8.5 (1.4) 3.2 (0.9) 4.6 (1.1) 10.0 (4.4) 5.0–12.0
%Hypo He, percentage of hypochromic red cells with an Hb content equivalent to -17 pg; %Hyper He, percentage of hyper-
chromic red cells with an Hb content equivalent to )49 pg; %Micro R, percentage of microcytic red cells with a volume
-60 fL; %Macro R, percentage of macrocytic red cells with a volume )120 fL.
calculated using the method of Pearson. Independent t-tests
were performed to detect statistical deviation between the
groups of patients; p-0.05 were considered to be statisti-
cally significant. Receiver operating characteristic (ROC)
curve analysis was used to evaluate the diagnostic perform-
ance of the new parameters. The k index was used to deter-
mine concordance between new and traditional parameters.
Results
The values obtained for the new four parameters
were normally distributed.
(%Hypo He, ps0.626; %Hyper He, ps0.288; %Micro
R, ps0.751 and %Macro R, ps0.093).
Reference ranges (95th central percentile) were cal-
culated from results obtained in the healthy subjects
group. The values of the RBC extended parameters in
the four groups of patients are summarized on Table
2.
Figure 1 shows the box and whiskers plot of the
values for %Hypo He in the different groups, while
Figure 2 shows the box and whiskers plot of the val-
ues for %Micro R in the different groups.
The correlation coefficients for the various para-
meters were: %Hypo He vs. MCH (rs–0.75); %Hyper
He vs. MCH (rs0.75); %Micro R vs. MCV (rs–0.91);
%Macro R vs. MCV (rs0.81). The values obtained for
the four new RBC extended parameters were statis-
tically different (p-0.0001) between the different
groups; the only exception was %Hypo He in cases of
IDA and thalassemia (ps0.3758). The IDA and b tha-
lassemia groups showed restricted erythropoiesis,
due to lack of iron or globin as demonstrated by the
low Ret He values. Healthy subjects and patients with
CKD undergoing therapy had Ret He concentrations
greater than the cut-off value of 29 pg.
Significant differences in %Hypo He values (p-
0.001) were detected when groups with restricted
erythropoiesis, such as those with IDA and b thalas-
semia were compared with patients with CKD and
normal individuals.
ROC curve analysis for %Hypo He in the diagnosis
of restricted erythropoiesis (Ret He -29 pg) showed
an area under the curve (AUC) of 0.963 w95% confi-
dence interval (CI), 0.928–0.985x at a cut-off threshold
of 1.8%; sensitivity 98.3%; specificity 91.1%.
The diagnostic performance of MCH and MCV for
the detection of restricted erythropoiesis (Ret He
-29 pg) was also evaluated. ROC analysis for MHC
showed an AUC of 0.924 (95% CI, 0.89–0.94) at a cut-
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Figure 2 Comparison of %Micro R between the three groups of patients with anemia: iron deficiency anemia (IDA), thalas-
semia carriers, chronic kidney disease (CKD) and the reference group.
The horizontal line in the center of the box shows the median value, the upper and lower limits of the box show the inter-
quartile range, and the whiskers show the minimum and maximum values for each group.
off threshold of 25.4 pg; sensitivity 86.5%; specificity
90.6%. ROC analysis results for MCV showed an AUC
of 0.90 (95% CI, 0.86–0.93) at a cut-off threshold of
80.8 fL; sensitivity 84.2%; specificity 89.5%.
Overall agreement between %Hypo He and Ret He
was 82.%, k index 0.656 (95% CI, 0.575–0.736).
Discussion
Disturbances in iron metabolism may occur in many
patients, the challenge is to identify these patients as
early as possible. However, this is not an easy task
because minimal hematological changes may be
present only. Careful interpretation of results is
required, together with the use of these additional
new parameters.
Development of new parameters may allow the
complete scope of disorders of iron metabolism to be
identified quickly and managed. Hematological indi-
ces and the new parameters measured with automat-
ed counters are sensitive for detecting small changes
in subpopulations of red cells. They hold promise for
the evaluation of iron-restricted erythropoiesis and
the status of iron metabolism. However, more studies
are needed.
In this study, we determined reference ranges for
the new RBC extended parameters. We did not find
any difference between males and females. The wide
reference range found for %Macro R (5%–12%) could
be attributed to the integration limits defined in the
calculation algorithm for this parameter. The manu-
facturer may want to reconsider these limits. As a
result of these limits, no patients with macrocytic ane-
mia were included in the study.
Patients with CKD received treatment in order to
maintain appropriate iron status and efficient eryth-
ropoiesis. Patients were stable with Hb concentrations
near desirable limits 110 g/L (19, 16), and values for
%Hyper He and %Macro R were within the reference
range. The %Hypo He values obtained in this group
of patients undergoing recombinant human erythro-
poietrin (r-HuEPO) therapy were statistically lower
(1.7%) than those that were iron deficient (16.2%). All
of these patients had mild anemia and %Hypo He val-
ues were above the reference range. The same find-
ings were noted for %Micro R.
Patients with uncomplicated b thalassemia and IDA
showed different results with respect to microcytic
and hypochromic red cells. Iron deficient erythropoi-
esis is characterized by the production of RBCs with
decreased Hb content resulting in a high percentage
of hypochromic cells (20). As anemia progresses the
number of microcytic cells increases. However,
patients with b thalassemia show erythrocytosis and
a high rate of microcytosis as a result of increased
erythropoiesis. Red cells in patients with b thalasse-
mia have a small volume due to impaired globin syn-
thesis (21). The %Micro R values in thalassemia
carriers were statistically different (mean 37.6%) com-
pared with values obtained in the IDA group (mean
16.5%), p-0.0001. Although our results are consistent
with previous publications which showed the RBC
count to be the most efficient single measurement for
the differential diagnosis of these two types of micro-
cytic anemia (22, 23), in our patients, the diagnostic
performance of the RBC count was better (AUC 0.944)
compared with the %Micro R (AUC 0.89).
The %Hypo He values in b thalassemia carriers
were above the reference range. This is due to inef-
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ficient erythropoiesis as a result of reduced synthesis
of intact Hb. These results did not differ from those
seen in patients with IDA (ps0.3785).
Comparing patients with restricted erythropoiesis
due to lack of iron (IDA) or globin (thalassemia) to
those individuals with normal erythropoiesis (refer-
ence group and patients on therapy), the diagnostic
performance of %Hypo He was excellent when com-
pared to Ret He.
Ret He, reported by all Sysmex XE analyzers (Sys-
mex Corporation, Kobe, Japan), assess the incorpor-
ation of iron into erythrocyte Hb. This parameter is
thus a direct estimate of the functional availability of
iron into the erythron (24–28). ROC curve analysis
revealed that a cut-off threshold of 1.8% for identi-
fying restricted erythropoiesis (defined by Ret He
-29 pg) produced a sensitivity of 98.3% and speci-
ficity of 91.1%. The AUC was 0.963 (p-0.0001).
Flow cytometry provides information about individ-
ual cell characteristics and is sensitive in detecting
small changes in the number of red cells with inade-
quate hemoglobinization and volume. The application
of flow fluorescence cytometry technology from
Sysmex allows for independent measurement of the
volume and Hb content of individual red cells. The
analysis of these new parameters could be performed
simultaneously in the course of routine blood cell
counts, with no incremental costs and without the
need for more blood.
We report the first results obtained for the new RBC
extended parameters derived from this technology,
including determination of the reference range in
healthy subjects and values in anemic patients with
red cells abnormalities. We report our observations
on the potential clinical utility of these new parame-
ters in the monitoring of erythropoietic function.
The availability of RBC extended parameters should
allow further assessment of their utility for diagnos-
ing disturbances of iron metabolism, the response to
iron or folate supplementation and the differential
diagnosis of microcytic anemias. Further studies are
needed in order to confirm our results.
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